<DOC>
	<DOCNO>NCT02772224</DOCNO>
	<brief_summary>Comparing efficacy safety drug-eluting balloon ( DEB ) treatment below-the-knee peripheral arterial occlusive disease conventional balloon angioplasty ( BA ) .</brief_summary>
	<brief_title>Efficacy Safety Paclitaxel-eluting Balloons Below Knee Peripheral Arterial Disease</brief_title>
	<detailed_description>Over past decade , percutaneous transluminal angioplasty ( PTA ) establish position treatment knee arterial occlusive disease intermittent claudication and/or critical limb ischemia . However , efficacy percutaneous transluminal angioplasty ( PTA ) conventional balloon , limited high 12-month restenosis target lesion revascularization ( TLR ) rate . Local delivery newer anti-proliferative drug via drug-eluting balloon ( DEBs ) recently show promising result treatment femoropopliteal disease , BTK area , reduction 3-month binary restenosis observe compare historical control treat PTA . Drug elute balloon three potential advantage : ( 1 ) homogenous drug transfer vessel wall ; ( 2 ) high drug concentration vessel wall time injury ; ( 3 ) absence stent delivery polymer . This study seek investigate long-term efficacy safety new drug ( Paclitaxel ) -eluting balloon ( DEB ) treatment knee peripheral arterial disease .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patients Peripheral vascular disease without diabetes . 2 . Rutherford class 26 . 3 . Target lesion diameter reduction least 50 % angiography , without past history intervention . 4 . Target vessel 2.010.0mm diameter lesion 4cm20cm length . 5 . Written inform consent sign patient representative 1 . Previous bypass surgery stent placement ipsilateral low limb 2 . History intolerance antiplatelet therapy , heparin , contrast medium . 3 . Bleeding diathesis ; 4 . Active systemic bacterial infection ; 5 . Severely impaired renal function ( serum creatinine level &gt; 2.5 mg/dL . 6 . Expected survival time le 24 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>